NCT05667623View on ClinicalTrials.gov

To Demonstrate the Superiority of IMP (1% OPA-15406 Ointment) to the Vehicle in Adult Patients With AD

PHASE3CompletedINTERVENTIONAL
Enrollment

270

Participants

Timeline

Start Date

February 6, 2023

Primary Completion Date

June 17, 2024

Study Completion Date

November 29, 2024

Conditions
Atopic Dermatitis (AD)
Interventions
DRUG

1% OPA-15406 Ointment

Twice-daily administration for 4 weeks/24 weeks.

OTHER

0% OPA-15406 Vehicle

Twice-daily administration for 4 weeks/24 weeks.

Trial Locations (1)

100044

Peking University People's Hospital, Beijing

Sponsors
All Listed Sponsors
lead

Otsuka Beijing Research Institute

INDUSTRY